title: Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.
abstract: The antiprogesterone steroid RU 486 (17 beta-hydroxy-11 beta-4-dimethyl-aminophenyl)17 alpha(1-propynyl)estra-4,9-dien-3-one) was given orally to 32 normally cycling women for 4 days, starting on the fourth day of the luteal phase. Uterine bleeding occurred on the third day of RU 486 administration in all 14 women treated with 100 mg/day, in 7 of the 8 women treated with 50 mg, and in 8 of 10 women receiving 25 mg/day. Premature luteal regression induced by RU 486 occurred in 8 women treated with 100 mg/day, in 3 treated with 50 mg, and in 2 receiving 25 mg/day. Plasma LH was measured every 15 min from 0800-1200 h for 5 days in 17 women. Mean LH levels decreased and pulsatile release disappeared in 7 of the 8 women treated with 100 mg, in 2 of 4 receiving 50 mg, and in 1 of 5 treated with 25 mg. RU 486 had no effect when given to 5 women with anovulatory cycles for 4 days starting on day 18 of the cycle.
  
  
  CONCLUSIONS
  1) RU 486, given to normally cycling women at midluteal phase, provokes uterine bleeding. 2) This effect occurs whether or not luteal regression is induced by the compound, indicating that RU 486 acts directly upon the endometrial tissue, very likely at the progesterone receptor level. 3) The drug may impair simultaneously or separately luteal function and gonadotropin secretion in a dose-dependent manner. 4) The lack of antiglucocorticosteroid activity, at the dosage of 100 mg/day, suggests that RU 486 may be useful for fertility control.
authors.forename: G
authors.initials: G
authors.lastname: Schaison
authors.forename: M
authors.initials: M
authors.lastname: George
authors.forename: N
authors.initials: N
authors.lastname: Lestrat
authors.forename: A
authors.initials: A
authors.lastname: Reinberg
authors.forename: E E
authors.initials: EE
authors.lastname: Baulieu
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000450:Aldosterone / Q000097:blood; D000858:Anovulation / Q000097:blood; D004958:Estradiol / Q000097:blood; D004963:Estrenes / Q000494:pharmacology*; D005260:Female; D006062:Gonadotropins / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008183:Luteal Phase / Q000187:drug effects*; D008598:Menstruation / Q000187:drug effects; D015735:Mifepristone; D010912:Pituitary-Adrenal Function Tests; D011374:Progesterone / Q000097:blood; D012083:Renin / Q000097:blood
chemical_list: D004963:Estrenes; D006062:Gonadotropins; D015735:Mifepristone; D000450:Aldosterone; D011374:Progesterone; D004958:Estradiol; D000324:Adrenocorticotropic Hormone; D012083:Renin; D006854:Hydrocortisone